Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a)

JAMA

2023-11-12

(Press-News.org) About The Study: In this phase 1 study of 48 participants with elevated lipoprotein(a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein(a) concentrations. The findings support further study of lepodisiran, which is a short interfering RNA directed at hepatic synthesis of apolipoprotein(a), an essential component necessary for assembly of lipoprotein(a) particles.

Authors: Steven E. Nissen, M.D., of the Cleveland Clinic Center for Clinical Research in Cleveland, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.21835)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being released to coincide with presentation at the American Heart Association’s Scientific Sessions 2023.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.23204?guestAccessKey=36be1cb8-a086-4f1e-ac7e-1ff334f94ccc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111223

END

ELSE PRESS RELEASES FROM THIS DATE:

Trial shows a single dose of an experimental therapy reduces lipoprotein(a), an important heart disease risk factor, more than 94% for nearly a year

2023-11-12

Cleveland: Findings from a phase 1 trial reported by a Cleveland Clinic physician show that a single dose of an experimental therapy produced greater than 94% reductions in blood levels of lipoprotein(a), a key driver of heart disease risk, with the results lasting for nearly a year. Results from the “Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein(a) Study” were presented today during a late-breaking science session at the American Heart ...

Gailen Marshall installed as ACAAI President

2023-11-12

ANAHEIM, Calif. (November 12, 2023) – Allergist Gailen Marshall, MD, PhD, of Jackson, MS, was installed as president of the American College of Allergy, Asthma and Immunology (ACAAI) at the ACAAI Annual Scientific Meeting on November 12 in Anaheim, Calif. Allergist James Tracy, DO, of Omaha, NE, was elected ACAAI president-elect. Other newly elected ACAAI officers are Cherie Zachary, MD, Eagan, MN as vice president and Kelly Maples, MD, Norfolk, VA as treasurer. Regents elected for three-year terms include Aikaterini Anagnostou, MD, MSc, PhD, Houston, Texas, Brian T. Kelly, MD, MA, Omaha, Nebraska and Mervat Nassef, MD, New York, New ...

Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

2023-11-12

About The Study: Among patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction treated with dapagliflozin in this randomized clinical trial, an initial estimated glomerular filtration rate (eGFR) decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that sodium-glucose cotransporter-2 inhibitors should not be interrupted or discontinued in response to an initial eGFR decline. Authors: Finnian R. Mc Causland, ...

2023 Joseph A. Johnson Award goes to Yale University professor of physics

2023-11-12

AIP and the National Society of Black Physicists congratulate Charles D. Brown II as the winner of the 2023 Joseph A. Johnson Award for Excellence. Dante O’Hara and Danielle Speller are also being recognized with Honorable Mentions. The Johnson Award, now in its fourth year, is given by AIP and NSBP to recognize early-career scientists who demonstrate scientific ingenuity and impactful mentorship and service – the core values of NSBP founder Joseph A. Johnson. “We are excited to recognize Dr. Brown’s impact on the physics community,” said Michael Moloney, CEO of AIP. ...

A high-risk antiphospholipid antibody profile matters in pediatric patients with antiphospholipid syndrome

2023-11-12

San Diego, CA, November 12, 2023 - A new study by Hospital for Special Surgery (HSS) investigators has found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients. The results were presented today in a poster session at American College of Rheumatology (ACR) Convergence 2023, the ACR’s annual meeting.1 “There are a lot of unanswered questions about how APS affects pediatric patients since evidence to date has been very limited,” said Jheel Pandya, MD, a pediatric rheumatology fellow at HSS and lead author of the research. “Our study reveals that an initial high-risk ...

Hormonal contraceptives in teens may alter risk assessment

2023-11-12

[Embargoed until 1 p.m. (ET) Sunday, Nov. 12] WASHINGTON – Hormonal contraceptives taken by adolescents may influence development of the brain in a way that alters the recognition of risks, a new study in rats suggests. Scientists at The Ohio State University are exploring how common synthetic hormones used for birth control affect the prefrontal cortex, an area of the brain that continues to develop throughout adolescence. The researchers found that myelination, the formation of protective coating on axons projecting from the main body of brain cells, increased in rats given hormonal birth control compared to untreated rats, while the number ...

Early-life stress changes more genes in brain than a head injury

2023-11-12

WASHINGTON – A surprising thing happened when researchers began exploring whether early-life stress compounds the effects of a childhood head injury on health and behavior later in life: In an animal study, stress changed the activation level of many more genes in the brain than were changed by a bump to the head. It’s already known that head injuries are common in young kids, especially from falling, and can be linked to mood disorders and social difficulties that emerge later in life. Adverse childhood experiences are also very ...

Summer wildfire and winter air pollution and particulates linked to different risks of heart attack and severe chest pain, new study finds

2023-11-12

Short-term increases in air pollution can cause problems for a lot of people, but especially to those with diagnosed or undiagnosed heart disease. But it’s not just a potential issue for pollution coming from cars and industrial processes. New research from Intermountain Health in Salt Lake City shows that pollutants trapped in lower, colder layers of air in mountain-region communities present sometimes higher risk for this population, while wildfire smoke from often distant locales may also impact risk. “We’re finding that air pollution is affecting ...

New study finds current dosing recommendations may not help patients achieve optimal vitamin D levels

2023-11-12

Low levels of Vitamin D have been shown to be associated with a higher risk of having a cardiac event, like a heart attack or stroke. For this reason, treatment by Vitamin D pills or injections are being investigated as a possible preventative method in these patients. However, two new studies from Intermountain Health in Salt Lake City have found that current dosing recommendations are not helping patients achieve optimal Vitamin D levels, suggesting that trials looking into the effectiveness of Vitamin D treatment to prevent cardiac events were not using appropriately sufficient doses, leading to inaccurate results. In their studies, Intermountain ...

Study finds poor ventilation use during CPR for out-of-hospital cardiac arrest

2023-11-12

The ventilation technique, also known as rescue breathing, commonly used during cardiopulmonary resuscitation (CPR) for people with cardiac arrest is often performed poorly by professional emergency responders, and this ineffective strategy is linked to significantly worse patient survival rates, according to a study supported by the National Institutes of Health. Ventilation involves administering breaths to a patient to provide life-sustaining oxygen and inflate the lungs when they stop breathing or during cardiac arrest, when the heart suddenly stops pumping blood. Among the nearly 2,000 ...

LAST 30 PRESS RELEASES:

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC